Update on point-of-care test for SARS-CoV-2
A game-changing point-of-care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch later in April. The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses. This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.
The VRI array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). The target gene for COVID-19 being used on the VRI array is ORF1ab, and for sarbecovirus (SARS, SARS-like, SARS-CoV-2) is the E gene, representing conserved regions of the genome which have been chosen for their high sensitivity and specificity.
The new VRI test will be conducted on Vivalytic, a point-of-care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable both of Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed, which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents onboard the cartridge, and utilises end point PCR. The test only requires a single nasal swab from the patient and an easy four-step process to be carried out by the user to run the patient sample.